<!DOCTYPE html>
<html lang="zh-TW">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>åœ‹å¤–ç½•è¦‹ï¼å­¤å…’è—¥ç›¸é—œæ³•è¦æ¯”è¼ƒï¼ˆä¿®è¨‚ç‰ˆï¼‰</title>
    <meta name="description" content="ç¾åœ‹ã€æ­ç›Ÿã€æ—¥æœ¬ã€åŠ æ‹¿å¤§ã€æ¾³æ´²åŠå°ç£ç½•è¦‹ç–¾ç—… / å­¤å…’è—¥åˆ¶åº¦ä¿®è¨‚ç‰ˆå°ç…§ï¼Œå«æœ€æ–°å®šç¾©ã€çå‹µæªæ–½ã€ä¿®æ­£æ¨™è¨»èˆ‡ä¾†æºã€‚">
    <meta data-version="1.1" data-last-updated="2025-09-09">
    <style>
        :root {
            --c-primary:#2563eb;
            --c-secondary:#0d6efd;
            --c-bg:#f5f7fa;
            --c-border:#e2e8f0;
            --c-danger:#dc3545;
            --c-warn:#f59e0b;
            --c-ok:#059669;
            --c-info:#0ea5e9;
            --c-muted:#64748b;
            --c-highlight:#fff8e1;
            --radius:10px;
        }
        body {
            font-family: "Microsoft JhengHei", Arial, sans-serif;
            margin:0;
            padding:20px;
            background:var(--c-bg);
            line-height:1.65;
            color:#1e293b;
        }
        .container {
            max-width:1450px;
            margin:0 auto;
            background:#fff;
            padding:32px 40px 60px;
            border-radius:var(--radius);
            box-shadow:0 6px 28px -8px rgba(0,0,0,.12);
            position:relative;
        }
        h1 {
            margin:0 0 28px;
            text-align:center;
            font-size:2.2rem;
            background:linear-gradient(135deg,var(--c-primary),#0ea5e9);
            -webkit-background-clip:text;
            color:transparent;
        }
        .meta-bar {
            display:flex;
            flex-wrap:wrap;
            gap:16px;
            font-size:.85rem;
            background:#eff6ff;
            border:1px solid #bfdbfe;
            padding:10px 16px;
            border-radius:var(--radius);
            margin-bottom:25px;
        }
        .badge {
            display:inline-block;
            padding:3px 10px 4px;
            font-size:.7rem;
            letter-spacing:.5px;
            border-radius:999px;
            background:#1d4ed8;
            color:#fff;
            margin-right:6px;
            vertical-align:middle;
        }
        .toc {
            background:#f1f5f9;
            border:1px solid var(--c-border);
            padding:22px 26px;
            border-radius:var(--radius);
            margin-bottom:38px;
            position:relative;
        }
        .toc h2 {
            margin:0 0 14px;
            font-size:1.25rem;
            color:#0f172a;
            display:flex;
            align-items:center;
            gap:8px;
        }
        .toc ul {
            list-style:none;
            padding:0;
            margin:0;
            columns:2;
        }
        .toc li {
            margin:6px 0;
            break-inside:avoid;
        }
        .toc a {
            text-decoration:none;
            color:var(--c-secondary);
            font-weight:500;
            position:relative;
            padding-left:4px;
        }
        .toc a:hover {
            text-decoration:underline;
            color:#1d4ed8;
        }
        .law-section {
            border:1px solid var(--c-border);
            border-radius:var(--radius);
            margin-bottom:55px;
            overflow:hidden;
            background:#ffffff;
        }
        .law-header {
            margin:0;
            padding:18px 24px;
            background:linear-gradient(120deg,#1e3a8a,#1d4ed8 50%,#2563eb);
            color:#fff;
            font-size:1.45rem;
            letter-spacing:.5px;
            display:flex;
            justify-content:space-between;
            flex-wrap:wrap;
            gap:12px;
        }
        .law-meta {
            background:#f8fafc;
            padding:14px 22px;
            font-size:.86rem;
            border-top:1px solid var(--c-border);
            border-bottom:1px solid var(--c-border);
            color:#475569;
            line-height:1.5;
        }
        .law-content {
            padding:30px 34px 40px;
        }
        .article {
            margin-bottom:32px;
            background:#ffffff;
            border:1px solid #e2e8f0;
            border-left:5px solid var(--c-primary);
            border-radius:6px;
            padding:18px 22px 20px;
            position:relative;
        }
        .article-title {
            font-weight:600;
            font-size:1.05rem;
            margin:0 0 14px;
            color:#0f172a;
            display:flex;
            align-items:center;
            gap:8px;
            flex-wrap:wrap;
        }
        .article-title .small-label {
            background:#e0f2fe;
            color:#0369a1;
            font-size:.6rem;
            padding:2px 6px 3px;
            border-radius:4px;
            letter-spacing:.5px;
        }
        .bilingual-content {
            display:grid;
            grid-template-columns:1fr 1fr;
            gap:20px;
        }
        .original-text, .translation {
            padding:14px 16px 16px;
            border-radius:8px;
            font-size:.92rem;
            position:relative;
            line-height:1.55;
        }
        .original-text {
            background:#f1f5f9;
            border:1px solid #e2e8f0;
        }
        .translation {
            background:#fffceb;
            border:1px solid #fde68a;
        }
        .lang-label {
            font-size:.65rem;
            font-weight:600;
            letter-spacing:.8px;
            color:#334155;
            background:#e2e8f0;
            padding:4px 8px;
            border-radius:999px;
            display:inline-block;
            margin-bottom:10px;
        }
        .highlight-box {
            background:#eef6ff;
            padding:18px 22px;
            border-left:6px solid #2563eb;
            border-radius:8px;
            margin:30px 0 10px;
            font-size:.93rem;
        }
        .highlight-box h3 {
            margin:0 0 14px;
            font-size:1rem;
            color:#1e3a8a;
            letter-spacing:.5px;
        }
        .point-list {
            margin:0;
            padding:0;
            list-style:none;
            display:grid;
            gap:10px;
        }
        .point-item {
            position:relative;
            padding-left:18px;
        }
        .point-item:before {
            content:"â—†";
            font-size:.6rem;
            color:#2563eb;
            position:absolute;
            left:0;
            top:4px;
        }
        .comparison-wrapper {
            overflow-x:auto;
            margin-top:10px;
        }
        table.comparison-table {
            width:100%;
            border-collapse:collapse;
            font-size:.85rem;
            min-width:1100px;
        }
        .comparison-table th, .comparison-table td {
            border:1px solid #e2e8f0;
            padding:10px 10px;
            text-align:left;
            vertical-align:top;
        }
        .comparison-table th {
            background:#1e3a8a;
            color:#ffffff;
            position:sticky;
            top:0;
            z-index:2;
            font-weight:600;
            letter-spacing:.5px;
        }
        .comparison-table tbody tr:nth-child(even) {
            background:#f8fafc;
        }
        .comparison-table td .note-inline {
            display:block;
            font-size:.7rem;
            color:#64748b;
            margin-top:4px;
            line-height:1.3;
        }
        .status-tag {
            display:inline-block;
            font-size:.6rem;
            padding:3px 6px 4px;
            font-weight:600;
            letter-spacing:.5px;
            border-radius:4px;
            margin-left:6px;
            vertical-align:middle;
        }
        .tag-updated { background:#d1fae5; color:#047857; }
        .tag-corrected { background:#fef3c7; color:#b45309; }
        .tag-removed { background:#fee2e2; color:#b91c1c; }
        .tag-new { background:#e0f2fe; color:#0369a1; }
        .updated, .corrected, .removed, .added {
            padding:2px 4px;
            border-radius:4px;
            font-size:.85em;
            font-weight:500;
        }
        .updated { background:#dcfce7; }
        .corrected { background:#fef9c3; }
        .removed { background:#fee2e2; text-decoration:line-through; }
        .added { background:#e0f2fe; }
        .footnotes {
            background:#f8fafc;
            border:1px solid var(--c-border);
            padding:24px 28px 30px;
            border-radius:var(--radius);
            font-size:.78rem;
            line-height:1.45;
            margin-top:60px;
        }
        .footnotes h3 {
            margin:0 0 14px;
            font-size:.95rem;
            color:#0f172a;
        }
        .footnotes ol {
            margin:0;
            padding-left:18px;
        }
        .footnotes li { margin:6px 0; }
        .callout {
            border:1px solid #cbd5e1;
            background:#ffffff;
            padding:16px 18px;
            border-radius:8px;
            margin:24px 0;
            display:flex;
            gap:14px;
            font-size:.9rem;
            position:relative;
        }
        .callout.info { border-color:#93c5fd; background:#eff6ff; }
        .callout.warn { border-color:#fcd34d; background:#fffbeb; }
        .callout.danger { border-color:#fca5a5; background:#fef2f2; }
        .callout strong { color:#0f172a; }
        .legend {
            display:flex;
            flex-wrap:wrap;
            gap:10px;
            margin:14px 0 4px;
            font-size:.65rem;
        }
        .legend span {
            background:#f1f5f9;
            border:1px solid #e2e8f0;
            padding:4px 8px;
            border-radius:6px;
            display:flex;
            align-items:center;
            gap:4px;
        }
        .legend code {
            background:#e2e8f0;
            padding:2px 4px;
            border-radius:4px;
            font-size:.65rem;
        }
        .revision-log {
            margin-top:55px;
            background:#ffffff;
            border:1px solid #e2e8f0;
            padding:20px 24px 26px;
            border-radius:var(--radius);
        }
        .revision-log h3 {
            margin:0 0 12px;
            font-size:1rem;
        }
        .revision-log ul {
            margin:0;
            padding-left:18px;
            font-size:.85rem;
            line-height:1.5;
        }
        .source-links {
            display:grid;
            gap:14px;
            grid-template-columns:repeat(auto-fill,minmax(260px,1fr));
            margin-top:14px;
        }
        .source-card {
            background:#f1f5f9;
            border:1px solid #e2e8f0;
            border-radius:8px;
            padding:12px 14px 14px;
            font-size:.7rem;
            line-height:1.35;
            position:relative;
        }
        .source-card h4 {
            margin:0 0 6px;
            font-size:.75rem;
            color:#0f172a;
        }
        .source-card a {
            word-break:break-all;
            color:#1d4ed8;
            text-decoration:none;
        }
        .source-card a:hover {
            text-decoration:underline;
        }
        .disclaimer {
            margin-top:60px;
            padding:20px 24px;
            background:#fef2f2;
            border:1px solid #fecaca;
            border-radius:var(--radius);
            font-size:.78rem;
            line-height:1.5;
            color:#991b1b;
        }
        .back-to-top {
            position:fixed;
            right:26px;
            bottom:26px;
            width:50px;
            height:50px;
            background:#2563eb;
            color:#fff;
            border:none;
            border-radius:50%;
            cursor:pointer;
            font-size:18px;
            display:none;
            box-shadow:0 4px 16px -4px rgba(0,0,0,.35);
            transition:.25s;
        }
        .back-to-top:hover { background:#1d4ed8; transform:translateY(-3px); }
        mark {
            background:#fde68a;
            padding:1px 3px;
            border-radius:4px;
        }
        @media (max-width:980px) {
            .bilingual-content { grid-template-columns:1fr; }
            .toc ul { columns:1; }
            .law-content { padding:26px 22px 30px; }
            .article { padding:16px 16px 18px; }
            h1 { font-size:1.85rem; }
        }
        @media (max-width:600px) {
            body { padding:12px; }
            .container { padding:22px 20px 50px; }
            .law-header { font-size:1.15rem; }
        }
    </style>
</head>
<body>
  <div class="container">
    <h1>ğŸŒ åœ‹å¤–ç½•è¦‹ï¼å­¤å…’è—¥æ³•è¦ç¾æ³å°ç…§ï¼ˆä¿®è¨‚ç‰ˆï¼‰</h1>

    <div class="meta-bar">
      <div><span class="badge">VERSION</span> 1.1 ä¿®è¨‚ç‰ˆ</div>
      <div><span class="badge" style="background:#059669;">æ›´æ–°æ—¥æœŸ</span> 2025-09-09</div>
      <div><span class="badge" style="background:#0ea5e9;">è¦†è“‹ç¯„åœ</span> å°ç£ / ç¾åœ‹ / æ­ç›Ÿ / æ—¥æœ¬ / åŠ æ‹¿å¤§ / æ¾³æ´²</div>
      <div><span class="badge" style="background:#9333ea;">èªè¨€</span> ä¸­è‹± / æ—¥æ–‡åŸæ–‡ç¯€éŒ„</div>
    </div>

    <div class="callout info">
      <div><strong>èªªæ˜ï¼š</strong>æœ¬æª”ç‚ºæ‚¨åŸå§‹ç‰ˆæœ¬ä¹‹ã€Œç³¾éŒ¯ + æ›´æ–° + ä¾†æºæ¨™è¨»ã€ä¿®è¨‚ç‰ˆã€‚ä¿ç•™åŸçµæ§‹ï¼Œå°ä¸æ­£ç¢ºæˆ–éæ™‚å…§å®¹ä»¥æ¨™ç±¤èˆ‡è¡Œå…§æ¨™è¨» (<span class="corrected">ä¿®æ­£</span> / <span class="removed">ç§»é™¤</span> / <span class="updated">æ›´æ–°</span>) è¡¨ç¤ºï¼›æ–°å¢è£œå……ä»¥ <span class="added">æ–°å¢</span> é¡¯ç¤ºã€‚</div>
    </div>

    <div class="legend">
      <span><code>updated</code> = æ›´æ–°æ•¸æ“š</span>
      <span><code>corrected</code> = ä¿®æ­£æ–‡ç¾©/äº‹å¯¦</span>
      <span><code>removed</code> = åˆªé™¤æˆ–æ¨™è¨˜éŒ¯èª¤åŸè¿°</span>
      <span><code>added</code> = æ–°å¢è£œå……</span>
    </div>

    <div class="toc">
      <h2>ğŸ“‹ ç›®éŒ„</h2>
      <ul>
        <li><a href="#usa-orphan-drug-act">ä¸€ã€ç¾åœ‹å­¤å…’è—¥æ³• (Orphan Drug Act)</a></li>
        <li><a href="#eu-orphan-regulation">äºŒã€æ­ç›Ÿå­¤å…’è—¥è¦å‰‡ (Reg. 141/2000)</a></li>
        <li><a href="#japan-intractable-disease-act">ä¸‰ã€æ—¥æœ¬ã€Šé›£ç—…æ³•ã€‹èˆ‡æŒ‡å®šé›£ç—…åˆ¶åº¦</a></li>
        <li><a href="#canada-rare-strategy">å››ã€åŠ æ‹¿å¤§ç½•è¦‹ç–¾ç—…ç­–ç•¥ç¾æ³</a></li>
        <li><a href="#australia-orphan-program">äº”ã€æ¾³æ´² TGA å­¤å…’è—¥åˆ¶åº¦</a></li>
        <li><a href="#comparison-table">å…­ã€ä¿®è¨‚å¾Œæ¯”è¼ƒè¡¨</a></li>
        <li><a href="#sources">ä¸ƒã€ä¾†æºèˆ‡åƒè€ƒé€£çµ</a></li>
        <li><a href="#revision-log">å…«ã€ä¿®è¨‚ç´€éŒ„</a></li>
        <li><a href="#disclaimer">ä¹ã€å…è²¬è²æ˜</a></li>
      </ul>
    </div>

    <!-- USA -->
    <section id="usa-orphan-drug-act" class="law-section">
      <h2 class="law-header">ä¸€ã€ç¾åœ‹å­¤å…’è—¥æ³• Orphan Drug Act (ODA)</h2>
      <div class="law-meta">
        åˆ¶å®šï¼š1983å¹´ | ä¸»ç®¡æ©Ÿé—œï¼šFDA OOPD | æœ€æ–°ä¸»è¦è®Šå‹•ï¼š<span class="updated">2017 ç¨…åˆ¶æ”¹é©å½±éŸ¿ç ”ç™¼æŠµå…æ¯”ä¾‹</span>
      </div>
      <div class="law-content">

        <div class="article">
          <div class="article-title">Section 526 - Designation æ ¸å¿ƒæ‘˜è¦ <span class="small-label">åŸæ„ä¿ç•™</span></div>
          <div class="bilingual-content">
            <div class="original-text">
              <div class="lang-label">EN</div>
              Manufacturer or sponsor may request designation if the drug is intended for a rare disease or condition and either (A) prevalence <200,000 persons in the US OR (B) no reasonable expectation of recovering development costs.
            </div>
            <div class="translation">
              <div class="lang-label">ä¸­æ–‡</div>
              è£½é€ å•†/ç”³è«‹äººå¯ç”³è«‹æŒ‡å®šï¼›æ¢ä»¶ç‚ºï¼šç”¨æ–¼ç½•è¦‹ç–¾ç—…ï¼Œä¸” (A) æ‚£è€… <20 è¬äººï¼Œæˆ– (B) ç„¡æ³•åˆç†å›æ”¶é–‹ç™¼æˆæœ¬ã€‚
            </div>
          </div>
        </div>

          <div class="article">
            <div class="article-title">Section 527 - 7 å¹´å¸‚å ´ç¨å  <span class="small-label">ä¿ç•™</span></div>
            <div class="bilingual-content">
              <div class="original-text">
                <div class="lang-label">EN</div>
                Upon approval for an orphan-designated indication, FDA shall not approve the same drug for the same use for 7 years (except statutory exceptions).
              </div>
              <div class="translation">
                <div class="lang-label">ä¸­æ–‡</div>
                ç²å¾—å­¤å…’é©æ‡‰ç—‡æ ¸å‡†å¾Œï¼Œæ–¼ 7 å¹´å…§ FDA ä¸å†æ ¸å‡†åŒè—¥åŒé©æ‡‰ç—‡ï¼ˆæ³•å®šä¾‹å¤–é™¤å¤–ï¼‰ã€‚
              </div>
            </div>
          </div>

          <div class="highlight-box">
            <h3>ç¾åœ‹é‡é»èˆ‡æ›´æ–°</h3>
            <ul class="point-list">
              <li class="point-item">ç½•è¦‹ç–¾ç—…å®šç¾©ï¼š<strong><200,000 äºº</strong> æˆ–ç„¡æ³•å›æ”¶æˆæœ¬ï¼ˆ21 U.S.C. Â§360bbï¼‰</li>
              <li class="point-item">å¸‚å ´ç¨å ï¼š7 å¹´ï¼ˆä¸ç­‰åŒè³‡æ–™ä¿è­·ï¼Œå¯ç–ŠåŠ  Pediatric Exclusivity 6 å€‹æœˆï¼‰</li>
              <li class="point-item">ç¨…æ”¶æŠµå…ï¼š<span class="removed">50%</span> â†’ <span class="corrected">ç¾è¡Œç´„ 25%ï¼ˆTCJA å¾Œï¼‰</span></li>
              <li class="point-item"><span class="added">æ¿€å‹µé …ï¼šå…/æ¸›ä½¿ç”¨è€…è²»ã€Protocol Assistanceã€Grant Program (FDA OOPD)</span></li>
            </ul>
          </div>

      </div>
    </section>

    <!-- EU -->
    <section id="eu-orphan-regulation" class="law-section">
      <h2 class="law-header">äºŒã€æ­ç›Ÿå­¤å…’è—¥è¦å‰‡ Regulation (EC) No 141/2000</h2>
      <div class="law-meta">
        ç”Ÿæ•ˆï¼š2000å¹´ | ä¸»ç®¡ï¼šEMA COMP | å…’ç§‘å®Œæˆå¯å»¶é•·è‡³ 12 å¹´ï¼ˆèˆ‡ Paediatric Regulation è¯å‹•ï¼‰
      </div>
      <div class="law-content">

        <div class="article">
          <div class="article-title">Article 3 - æŒ‡å®šæ¢ä»¶ æ‘˜è¦ <span class="small-label">ä¿ç•™</span></div>
          <div class="bilingual-content">
            <div class="original-text">
              <div class="lang-label">EN</div>
              (a) Lifeâ€‘threatening or chronically debilitating & prevalence â‰¤5 in 10,000 OR (b) insufficient return without incentives; AND (c) no satisfactory method or significant benefit over existing.
            </div>
            <div class="translation">
              <div class="lang-label">ä¸­æ–‡</div>
              (a) å¨è„…ç”Ÿå‘½ / é•·æœŸè¡°å¼± ä¸” ç››è¡Œç‡ â‰¤5/10,000ï¼Œæˆ– (b) ç„¡çå‹µç„¡è¶³å¤ å›å ±ï¼›ä¸” (c) ç„¡æ»¿æ„ç™‚æ³•æˆ–å…·é¡¯è‘—æ•ˆç›Šã€‚
            </div>
          </div>
        </div>

        <div class="highlight-box">
          <h3>æ­ç›Ÿé‡é»èˆ‡è£œå……</h3>
          <ul class="point-list">
            <li class="point-item">ç››è¡Œç‡é–€æª»ï¼šâ‰¤5/10,000ï¼ˆä»¥ EU ç¸½äººå£æ¨ä¼°ï¼‰</li>
            <li class="point-item">å¸‚å ´ç¨å ï¼š10 å¹´ï¼›<span class="added">ç¬¬ 6 å¹´èµ·è‹¥å–ªå¤±ã€Œsignificant benefitã€æˆ–ä¾›æ‡‰ä¸è¶³å¯å‰Šæ¸›</span></li>
            <li class="point-item"><span class="added">å…’ç§‘è¨ˆç•«å®Œæˆï¼šå¯å»¶é•·è‡³ 12 å¹´ï¼ˆReg. (EC) 1901/2006ï¼‰</span></li>
            <li class="point-item">æ¿€å‹µï¼šé›†ä¸­å¯©æŸ¥ã€è²»ç”¨æ¸›å…ã€ä¸­å°ä¼æ¥­ (SME) æ”¯æŒ</li>
          </ul>
        </div>

      </div>
    </section>

    <!-- Japan -->
    <section id="japan-intractable-disease-act" class="law-section">
      <h2 class="law-header">ä¸‰ã€æ—¥æœ¬ã€Šé›£ç—…æ³•ã€‹èˆ‡ã€ŒæŒ‡å®šé›£ç—…ã€åˆ¶åº¦</h2>
      <div class="law-meta">
        æ³•å¾‹ï¼š2014 åˆ¶å®š / 2015 æ–½è¡Œ | ä¸»ç®¡ï¼šåšç”ŸåŠ´åƒçœ | åˆ¶åº¦é‡é»ï¼šé†«ç™‚è²»åŠ©æˆ + ç ”ç©¶æ¨é€²
      </div>
      <div class="law-content">

        <div class="article">
          <div class="article-title">æŒ‡å®šé›£ç—… ä¸»è¦è¦ä»¶ <span class="small-label">ä¿®æ­£</span></div>
          <div class="bilingual-content">
            <div class="original-text">
              <div class="lang-label">åŸæ–‡ç¯€ç¾©</div>
              ç—…å› æœªè§£ã€ç„¡æ ¹æ²»ç™‚æ³•ã€é•·æœŸç™‚é¤Šã€æ‚£è€…æ•¸ä½ã€å®¢è§€è¨ºæ–·åŸºæº–æˆç«‹ã€‚
            </div>
            <div class="translation">
              <div class="lang-label">ä¸­æ–‡</div>
              æ—¥æœ¬ç¾è¡ŒæŒ‡å®šé›£ç—…è€ƒé‡äº”è¦ç´ ï¼šâ‘  ç™¼ç—…æ©Ÿåºä¸æ˜ â‘¡ ç„¡ç¢ºç«‹æ²»ç™’ç™‚æ³• â‘¢ é•·æœŸç™‚é¤Šéœ€è¦ â‘£ æ‚£è€…æ•¸ä½ï¼ˆç´„ <span class="corrected">äººå£ 0.1%</span> é–€æª»æ°´æº–ï¼Œç”¨æ–¼æ”¿ç­–åˆ¤æ–·ï¼Œéåƒ…æ—©æœŸã€Œ5è¬äººã€å–®ä¸€æ•¸å­—ï¼‰â‘¤ æœ‰å®¢è§€è¨ºæ–·åŸºæº–ã€‚
            </div>
          </div>
        </div>

        <div class="highlight-box">
          <h3>æ—¥æœ¬é‡é»</h3>
          <ul class="point-list">
            <li class="point-item"><span class="removed">ã€Œæ‚£è€…å°‘æ–¼5è¬äººã€å–®ä¸€è¡¨è¿°</span> â†’ <span class="corrected">æ”¹ç‚ºæ”¿ç­–å¯¦å‹™ç¶œåˆé–€æª»ï¼ˆç´„äººå£ 0.1%ï¼‰ä¸¦çµåˆå…¶ä»–æ¢ä»¶</span></li>
            <li class="point-item">é†«ç™‚è²»åŠ©æˆï¼šç¬¦åˆæ‰€å¾—èˆ‡é‡ç—‡åˆ†é¡è€…éƒ¨åˆ†è² æ“”æ¸›å…</li>
            <li class="point-item">é‡è¦–ï¼šå®¢è§€è¨ºæ–·æ¨™æº– & ç ”ç©¶ç™»éŒ„ï¼ˆé›£ç—…æƒ…å ±ä¸­å¿ƒï¼‰</li>
            <li class="point-item"><span class="added">èˆ‡å‚³çµ±ã€Œå­¤å…’è—¥å°ˆå±¬å¸‚å ´ç¨å ã€æ¦‚å¿µä¸åŒï¼Œåé‡æ‚£è€…ä¿éšœèˆ‡ç ”ç©¶ç¶²çµ¡</span></li>
          </ul>
        </div>

      </div>
    </section>

    <!-- Canada -->
    <section id="canada-rare-strategy" class="law-section">
      <h2 class="law-header">å››ã€åŠ æ‹¿å¤§ç½•è¦‹ç–¾ç—…ç­–ç•¥ï¼ˆéå°ˆæ³•ï¼‰</h2>
      <div class="law-meta">
        ç¾æ³ï¼šç„¡æ­£å¼ã€Œå­¤å…’è—¥æ³•ã€ | ç­–ç•¥ï¼š2023 National Strategy for Drugs for Rare Diseasesï¼ˆ10 å„„åŠ å…ƒ / 3 å¹´ï¼‰
      </div>
      <div class="law-content">

        <div class="article">
          <div class="article-title">åˆ¶åº¦ç¾æ³ <span class="small-label">ä¿®æ­£</span></div>
          <div class="bilingual-content">
            <div class="original-text">
              <div class="lang-label">åŸæè¿°</div>
              <span class="removed">2019å¹´å¯¦æ–½ Orphan Drug Frameworkï¼›å®šç¾© <1/2000ï¼›å¸‚å ´ç¨å  8 å¹´ã€‚</span>
            </div>
            <div class="translation">
              <div class="lang-label">ä¿®è¨‚</div>
              <span class="corrected">åŠ æ‹¿å¤§å°šæœªå®Œæˆå­¤å…’è—¥å°ˆæ³•ç«‹æ³•ã€‚8 å¹´è³‡æ–™ä¿è­·å±¬ä¸€èˆ¬å‰µæ–°è—¥è¦å‰‡ï¼ˆéå­¤å…’å°ˆå±¬ï¼‰ã€‚ã€Œ<1/2,000ã€åƒ…ç‚ºéƒ¨åˆ†è©•ä¼°åƒè€ƒï¼Œç„¡ç¡¬æ€§æ³•è¦é–€æª»ã€‚2023 å¹´å•Ÿå‹•å…¨åœ‹è³‡åŠ©ç­–ç•¥ï¼Œèšç„¦åŠ é€Ÿå¯åŠã€å”èª¿ HTA / å®šåƒ¹èˆ‡è³‡æ–™å…±äº«ã€‚</span>
            </div>
          </div>
        </div>

        <div class="highlight-box">
          <h3>åŠ æ‹¿å¤§é‡é»</h3>
          <ul class="point-list">
            <li class="point-item">ç¼ºä¹çµ±ä¸€æ³•å®šç½•è¦‹ç–¾ç—…å®šç¾©ï¼ˆå¤šæ©Ÿæ§‹æ¡å€‹æ¡ˆèˆ‡åœ‹éš›åƒè€ƒï¼‰</li>
            <li class="point-item">æ¿€å‹µç›¸å°å¼±æ–¼ç¾/æ­ï¼›ä¾è³´æ³›ç”¨è³‡æ–™ä¿è­·ï¼ˆ8 å¹´ + å¯èƒ½ 6 å€‹æœˆå…’ç§‘ï¼‰</li>
            <li class="point-item"><span class="added">ç­–ç•¥é‡é»ï¼šå…¬å¹³å¯åŠã€çµ±ä¸€ HTAã€è³‡æ–™äº’é€šã€æ‚£è€…åƒèˆ‡</span></li>
          </ul>
        </div>

      </div>
    </section>

    <!-- Australia -->
    <section id="australia-orphan-program" class="law-section">
      <h2 class="law-header">äº”ã€æ¾³æ´² TGA å­¤å…’è—¥åˆ¶åº¦</h2>
      <div class="law-meta">
        è¨ˆç•«å‰µç«‹ï¼š1998ï¼ˆ2017 æ”¹ç‰ˆï¼‰ | ä¸»ç®¡ï¼šTGA | æ ¸å¿ƒï¼šè²»ç”¨æ¸›å… + æŒ‡å®šç¨‹åº
      </div>
      <div class="law-content">

        <div class="article">
          <div class="article-title">æŒ‡å®šæ¢ä»¶ <span class="small-label">ä¿®æ­£</span></div>
          <div class="bilingual-content">
            <div class="original-text">
              <div class="lang-label">åŸæè¿°</div>
              <span class="removed">å°‘æ–¼ 2,000 äººï¼›5 å¹´å¸‚å ´ç¨å ã€‚</span>
            </div>
            <div class="translation">
              <div class="lang-label">ä¿®è¨‚</div>
              <span class="corrected">ç¾è¡Œæ¡ç”¨ï¼šç››è¡Œç‡ <5/10,000ï¼ˆå°é½Š EU é–€æª»ï¼‰æˆ–ç¶“è­‰æ˜åœ¨ç¼ºä¹æ¿€å‹µä¸‹å•†æ¥­ä¸å¯è¡Œã€‚ç„¡å°ˆå±¬å­¤å…’ã€Œå¸‚å ´ç¨å æœŸã€ï¼Œé‡é»ç‚ºè²»ç”¨æ¸›å…èˆ‡ç›£ç®¡å”åŠ©ã€‚</span>
            </div>
          </div>
        </div>

        <div class="highlight-box">
          <h3>æ¾³æ´²é‡é»</h3>
          <ul class="point-list">
            <li class="point-item">è²»ç”¨æ¸›å…ï¼ˆè©•ä¼° / ç”³è«‹è²»ï¼‰</li>
            <li class="point-item">ç„¡ç¨ç«‹ Orphan Exclusivity æ¢æ¬¾</li>
            <li class="point-item">å¯ä½µç”¨å„ªå…ˆå¯©è©• (Priority/Limited evaluation) è¦æ ¼ï¼ˆæ¢ä»¶ä¸åŒï¼‰</li>
            <li class="point-item"><span class="added">èšç„¦å°å‹å¸‚å ´ç§‘å­¸èˆ‡è²»ç”¨éšœç¤™é™ä½</span></li>
          </ul>
        </div>

      </div>
    </section>

    <!-- Comparison Table -->
    <section id="comparison-table" class="law-section">
      <h2 class="law-header">å…­ã€å„å¸æ³•è½„å€æ¯”è¼ƒï¼ˆä¿®è¨‚å¾Œï¼‰</h2>
      <div class="law-content">

        <div class="comparison-wrapper">
          <table class="comparison-table">
            <thead>
              <tr>
                <th>é …ç›®</th>
                <th>å°ç£</th>
                <th>ç¾åœ‹</th>
                <th>æ­ç›Ÿ</th>
                <th>æ—¥æœ¬</th>
                <th>åŠ æ‹¿å¤§</th>
                <th>æ¾³æ´²</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td><strong>æ³•å¾‹ / åˆ¶åº¦åç¨±</strong></td>
                <td>ç½•è¦‹ç–¾ç—…é˜²æ²»åŠè—¥ç‰©æ³•</td>
                <td>Orphan Drug Act</td>
                <td>Reg. 141/2000</td>
                <td>é›£ç—…æ³• + æŒ‡å®šé›£ç—…åˆ¶åº¦</td>
                <td><span class="corrected">ç„¡å°ˆæ³•ï¼ˆ2023 ç½•è¦‹ç–¾ç—…ç­–ç•¥ï¼‰</span></td>
                <td>TGA Orphan Drug Program</td>
              </tr>
              <tr>
                <td><strong>ç½•è¦‹/æŒ‡å®šé–€æª»</strong></td>
                <td>ç››è¡Œç‡ â‰¤1/10,000</td>
                <td><200,000 äººæˆ–æˆæœ¬ä¸å¯å›æ”¶</td>
                <td>â‰¤5/10,000</td>
                <td><span class="corrected">ç¶œåˆæ¢ä»¶ï¼ˆå«æ‚£è€…æ•¸ç´„ <0.1% äººå£ + å…¶ä»–è¦ä»¶ï¼‰</span><span class="note-inline">éå–®ä¸€å›ºå®šæ•¸å­—</span></td>
                <td><span class="corrected">ç„¡çµ±ä¸€å®šç¾©ï¼ˆåƒè€ƒåœ‹éš›é–€æª»ï¼‰</span></td>
                <td><span class="corrected"><5/10,000 æˆ–ç„¡å•†æ¥­å¯è¡Œæ€§</span></td>
              </tr>
              <tr>
                <td><strong>å¸‚å ´ç¨å  / æ’ä»–</strong></td>
                <td><span class="corrected">ç„¡å…¸å‹ Orphan Exclusivityï¼›æä¾›è³‡æ–™ä¿è­·/çµ¦ä»˜æ”¯æŒ</span></td>
                <td>7 å¹´ Orphan Exclusivity</td>
                <td>10 å¹´ï¼ˆå¯ç¸®çŸ­ / å…’ç§‘è‡³ 12 å¹´ï¼‰</td>
                <td>ç„¡å­¤å…’å°ˆå±¬ç¨å ï¼ˆé†«ç™‚è²»åŠ©æˆï¼‰</td>
                <td>ç„¡ï¼ˆä¸€èˆ¬æ–°è—¥ 8 å¹´è³‡æ–™ä¿è­·ï¼‰</td>
                <td><span class="corrected">ç„¡å°ˆå±¬å­¤å…’ç¨å ï¼›è²»ç”¨æ¸›å…</span></td>
              </tr>
              <tr>
                <td><strong>ç¨…å‹™ / è²¡æ”¿æ¿€å‹µ</strong></td>
                <td>éƒ¨åˆ†ç ”ç™¼/æŠ•è³‡æŠµæ¸›ï¼ˆç”¢å‰µæ¢ä¾‹ï¼‰</td>
                <td><span class="corrected">è‡¨åºŠç ”ç™¼æŠµå… 25%</span></td>
                <td>Member State è‡ªè¨‚ï¼ˆéƒ¨ä»½æ¸›å…ï¼‰</td>
                <td>ç ”ç©¶è£œåŠ© / åŠ©æˆé‡‘</td>
                <td>æœ‰é™ï¼ˆå°ˆæ¡ˆå¼ï¼‰</td>
                <td>ç„¡å°ˆå±¬ç¨…å‹™ï¼›è²»ç”¨æ¸›å…</td>
              </tr>
              <tr>
                <td><strong>å¯©æŸ¥è²»ç”¨æ¸›å…</strong></td>
                <td>æœ‰</td>
                <td>æœ‰ï¼ˆUser Fee æ¸›å…/è±å…ï¼‰</td>
                <td>æœ‰ï¼ˆProtocol Assistance å„ªæƒ ï¼‰</td>
                <td>æœ‰</td>
                <td>éƒ¨åˆ†æƒ…æ³</td>
                <td>æœ‰ï¼ˆæŒ‡å®šå¾Œå¤§å¹…æ¸›å…ï¼‰</td>
              </tr>
              <tr>
                <td><strong>å„ªå…ˆ / åŠ é€Ÿå¯©æŸ¥</strong></td>
                <td>æœ‰ï¼ˆå¿«é€Ÿå¯©æŸ¥æ©Ÿåˆ¶ï¼‰</td>
                <td>Priority Review / Fast Track / Breakthrough å¯ç–ŠåŠ </td>
                <td>å¯é›†ä¸­å¯©è©• + PRIME</td>
                <td>å€‹æ¡ˆè™•ç†</td>
                <td>å€‹æ¡ˆï¼ˆPriority Reviewï¼‰</td>
                <td>Priority / Provisional / Orphan æ”¯æ´</td>
              </tr>
              <tr>
                <td><strong>è³‡æ–™ / å…’ç§‘å»¶é•·</strong></td>
                <td>è³‡æ–™ä¿è­·æŒ‰è—¥å“æ³•ä¸€èˆ¬è¦ç¯„</td>
                <td>Pediatric å»¶é•· 6 å€‹æœˆï¼ˆè‹¥åˆæ ¼ï¼‰</td>
                <td>å…’ç§‘å¯å»¶é•·è‡³ 12 å¹´</td>
                <td>ç„¡ Orphan å°ˆå±¬å»¶é•·</td>
                <td>8 å¹´ + 6 å€‹æœˆï¼ˆå…’ç§‘ï¼‰</td>
                <td>æŒ‰ä¸€èˆ¬è—¥å“è¦å‰‡</td>
              </tr>
              <tr>
                <td><strong>é†«ç™‚ / è²»ç”¨æ”¯æŒ</strong></td>
                <td>å¥ä¿ + ç‰¹å®šè£œåŠ©</td>
                <td>æœ‰é™ï¼ˆå· / ä¿éšªå·®ç•°ï¼‰</td>
                <td>æœƒå“¡åœ‹è‡ªè¨‚</td>
                <td>é†«ç™‚è²»åŠ©æˆåˆ¶åº¦å¥å…¨</td>
                <td>çœç´šå·®ç•° / ç­–ç•¥è³‡åŠ©</td>
                <td>å…¬å…±è³‡åŠ©æœ‰é™</td>
              </tr>
              <tr>
                <td><strong>æ‚£è€…è³‡æ–™ç™»éŒ„</strong></td>
                <td>é€æ­¥å»ºç«‹ï¼ˆç–¾ç®¡ç½²/ç ”ç©¶è¨ˆç•«ï¼‰</td>
                <td>å¤šé‡ç™»éŒ„ / NIH / è‡ªé¡˜æ€§</td>
                <td>æ­ç›Ÿç¶²çµ¡ / Orphanet</td>
                <td>æŒ‡å®šé›£ç—…ç™»éŒ„åˆ¶åº¦</td>
                <td>åˆ†æ•£å¼ / å°ˆé¡Œè¨ˆç•«</td>
                <td>åˆ†æ•£ / å°ˆæ¥­å­¸æœƒ</td>
              </tr>
            </tbody>
          </table>
        </div>

        <div class="callout warn">
          <strong>è§£è®€æç¤ºï¼š</strong>å„åœ‹ã€Œå¸‚å ´ç¨å ã€æ³•å¾‹æ€§è³ªä¸¦éå®Œå…¨å¯æ¯”ï¼›é ˆå€åˆ†ã€Œæ³•å®šæ’ä»–ã€èˆ‡ã€Œè³‡æ–™ä¿è­· / è¡Œæ”¿æ¿€å‹µã€ã€‚
        </div>

      </div>
    </section>

    <!-- Sources -->
    <section id="sources" class="law-section">
      <h2 class="law-header">ä¸ƒã€ä¾†æºèˆ‡åƒè€ƒé€£çµ</h2>
      <div class="law-content">

        <div class="source-links">
          <div class="source-card">
            <h4>ç¾åœ‹ Orphan Drug Act</h4>
            <a href="https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section360bb" target="_blank">21 U.S.C. Â§360bbâ€“360dd</a>
          </div>
          <div class="source-card">
            <h4>FDA Orphan è³‡æ–™åº«</h4>
            <a href="https://www.accessdata.fda.gov/scripts/opdlisting/oopd/" target="_blank">OOPD Listing</a>
          </div>
          <div class="source-card">
            <h4>Tax Cuts and Jobs Act</h4>
            <a href="https://www.congress.gov/bill/115th-congress/house-bill/1" target="_blank">TCJA 2017</a>
          </div>
          <div class="source-card">
            <h4>EU Reg. 141/2000</h4>
            <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32000R0141" target="_blank">EUR-Lex 141/2000</a>
          </div>
          <div class="source-card">
            <h4>EU Orphan Guidance</h4>
            <a href="https://www.ema.europa.eu/en/human-regulatory/overview/orphan-designation" target="_blank">EMA Orphan Page</a>
          </div>
          <div class="source-card">
            <h4>å…’ç§‘è¦å‰‡</h4>
            <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32006R1901" target="_blank">Reg. (EC) 1901/2006</a>
          </div>
          <div class="source-card">
            <h4>æ—¥æœ¬ é›£ç—…æ³•</h4>
            <a href="https://elaws.e-gov.go.jp/document?lawid=426AC0000000050" target="_blank">e-Gov æ³•ä»¤</a>
          </div>
          <div class="source-card">
            <h4>æ—¥æœ¬ æŒ‡å®šé›£ç—…</h4>
            <a href="https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000084783.html" target="_blank">åšç”ŸåŠ´åƒçœ</a>
          </div>
          <div class="source-card">
            <h4>åŠ æ‹¿å¤§ç­–ç•¥æ–°èç¨¿</h4>
            <a href="https://www.canada.ca/en/health-canada/news/2023/03/supporting-canadians-with-rare-diseases.html" target="_blank">2023 Strategy</a>
          </div>
          <div class="source-card">
            <h4>æ“¬è­°å­¤å…’è—¥æ”¿ç­–èƒŒæ™¯</h4>
            <a href="https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/initiatives/orphan-drugs.html" target="_blank">Health Canada</a>
          </div>
          <div class="source-card">
            <h4>æ¾³æ´² Orphan æŒ‡å—</h4>
            <a href="https://www.tga.gov.au/resources/resource/guidance/orphan-drug-designation" target="_blank">TGA Guidance</a>
          </div>
          <div class="source-card">
            <h4>æ¾³æ´² è²»ç”¨æ¸›å…</h4>
            <a href="https://www.tga.gov.au/how-we-regulate/fees/orphan-drugs" target="_blank">TGA Fees</a>
          </div>
          <div class="source-card">
            <h4>å°ç£ æ³•è¦</h4>
            <a href="https://law.moj.gov.tw/LawClass/LawAll.aspx?pcode=L0020037" target="_blank">ç½•è¦‹ç–¾ç—…é˜²æ²»åŠè—¥ç‰©æ³•</a>
          </div>
          <div class="source-card">
            <h4>å°ç£ è¡›ç¦éƒ¨</h4>
            <a href="https://www.mohw.gov.tw" target="_blank">MOHW å®˜ç¶²</a>
          </div>
          <div class="source-card">
            <h4>Orphanet / åœ‹éš›</h4>
            <a href="https://www.orpha.net" target="_blank">Orphanet</a>
          </div>
          <div class="source-card">
            <h4>NORD</h4>
            <a href="https://rarediseases.org/" target="_blank">NORD</a>
          </div>
          <div class="source-card">
            <h4>EURORDIS</h4>
            <a href="https://www.eurordis.org/" target="_blank">EURORDIS</a>
          </div>
        </div>

        <div class="footnotes">
          <h3>è¨»é‡‹ï¼ˆFootnotesï¼‰</h3>
          <ol>
            <li>ç¾åœ‹ç¨…æ”¶æŠµå…ï¼š2017 ä»¥å‰æœ€é«˜ 50%ï¼ŒTax Cuts and Jobs Act å¾Œæ”¹ç‚º 25% ä¸Šé™ã€‚</li>
            <li>æ—¥æœ¬ã€Œæ‚£è€…æ•¸ã€ä¸¦éå”¯ä¸€é–€æª»ï¼Œæ”¿ç­–æ–‡ä»¶ä»¥ã€Œäººå£ç´„ 0.1% ä»¥ä¸‹ã€ä½œåƒè€ƒéšå±¤ã€‚</li>
            <li>åŠ æ‹¿å¤§å°šç„¡å®šæ³•å®šç››è¡Œç‡ï¼ŒHTA èˆ‡ç­–ç•¥å±¤é¢æ¡ˆä¾‹å¼è™•ç†ã€‚</li>
            <li>æ¾³æ´² 2017 å¾Œæ¡å°é½Š EU çš„ç››è¡Œç‡é‚è¼¯ï¼ˆ<5/10,000ï¼‰ï¼Œå»¢é™¤èˆŠæœ‰å›ºå®šäººæ•¸å¼è¡¨è¿°ã€‚</li>
            <li>æ­ç›Ÿå¸‚å ´ç¨å å¯å› ã€Œå……åˆ†ä¾›æ‡‰ / significant benefit å–ªå¤±ã€è¢«å‰Šæ¸›ï¼Œå…’ç§‘å¯å»¶é•·ã€‚</li>
            <li>ã€Œå¸‚å ´ç¨å ã€èˆ‡ã€Œè³‡æ–™ä¿è­·ã€ï¼šå…©è€…æ³•å¾‹æ•ˆæœèˆ‡é©ç”¨ç¯„åœä¸åŒï¼Œéœ€é¿å…æ··ç”¨ã€‚</li>
          </ol>
        </div>

      </div>
    </section>

    <!-- Revision Log -->
    <section id="revision-log" class="revision-log">
      <h3>å…«ã€ä¿®è¨‚ç´€éŒ„</h3>
      <ul>
        <li><strong>v1.1 (2025-09-09)ï¼š</strong>ä¿®æ­£ç¾åœ‹ç¨…æ”¶æŠµå…æ•¸æ“šï¼›æ—¥æœ¬æŒ‡å®šé›£ç—…æ¢ä»¶æ”¹ç‚ºå¤šè¦ç´ ï¼›åŠ æ‹¿å¤§æ”¹ç‚ºç­–ç•¥æè¿°ï¼›æ¾³æ´²å®šç¾©æ”¹ç‚º <5/10,000ï¼›åˆªé™¤ä¸å¯¦ã€Œ5 å¹´å¸‚å ´ç¨å ã€ï¼›æ¯”è¼ƒè¡¨é‡æ§‹ã€‚</li>
        <li><strong>v1.0 (åŸå§‹ç‰ˆæœ¬)ï¼š</strong>å«éæ™‚èˆ‡éŒ¯èª¤æ•¸æ“šï¼ˆç¨…æ”¶ 50%ã€æ—¥æœ¬ 5 è¬äººã€æ¾³æ´² 2,000 äººç­‰ï¼‰ã€‚</li>
      </ul>
    </section>

    <!-- Disclaimer -->
    <section id="disclaimer" class="disclaimer">
      <strong>å…è²¬è²æ˜ï¼š</strong>æœ¬æ–‡ä»¶ç‚ºæ•™è‚²èˆ‡æ”¿ç­–ç ”ç©¶åƒè€ƒç”¨é€”ï¼Œéæ³•å¾‹æ„è¦‹ã€‚æ­£å¼é©ç”¨æ‡‰ä»¥å„å¸æ³•è½„å€ä¸»ç®¡æ©Ÿé—œæœ€æ–°å…¬å¸ƒã€å®˜æ–¹å…¬å ±èˆ‡åŸæ–‡æ³•è¦ç‚ºæº–ã€‚å°æ–¼åŸºæ–¼æœ¬æ–‡æ¡å–ä¹‹ä»»ä½•è¡Œå‹•ï¼Œè«‹å…ˆè«®è©¢å°ˆæ¥­æ³•å¾‹èˆ‡æ³•è¦äº‹å‹™é¡§å•ã€‚
    </section>

  </div>

  <button class="back-to-top" title="å›åˆ°é ‚éƒ¨" onclick="window.scrollTo({top:0,behavior:'smooth'})">â†‘</button>

  <script>
    const backBtn = document.querySelector('.back-to-top');
    window.addEventListener('scroll',() => {
      if(window.scrollY > 320){
        backBtn.style.display='block';
      } else {
        backBtn.style.display='none';
      }
    });

    // å¹³æ»‘éŒ¨é»
    document.querySelectorAll('a[href^="#"]').forEach(a=>{
      a.addEventListener('click',e=>{
        const id = a.getAttribute('href');
        if(id.length>1){
          e.preventDefault();
          const target = document.querySelector(id);
          if(target){ target.scrollIntoView({behavior:'smooth',block:'start'}); }
        }
      });
    });
  </script>
</body>
</html>
